News
09-05-2008, 07:10 AM
Agendia, a world leader in molecular cancer diagnostics, announced the launch of TargetPrint(R), a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumor biopsies.
More... (http://www.medicalnewstoday.com/articles/120337.php)
More... (http://www.medicalnewstoday.com/articles/120337.php)